297 related articles for article (PubMed ID: 36250069)
1. An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms.
Arthur HM; Roman BL
Front Med (Lausanne); 2022; 9():973964. PubMed ID: 36250069
[TBL] [Abstract][Full Text] [Related]
2. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions.
Snodgrass RO; Chico TJA; Arthur HM
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513792
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models of Hereditary Hemorrhagic Telangiectasia.
Hwan Kim Y; Vu PN; Choe SW; Jeon CJ; Arthur HM; Vary CPH; Lee YJ; Oh SP
Circ Res; 2020 Oct; 127(9):1122-1137. PubMed ID: 32762495
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
Tillet E; Bailly S
Front Genet; 2014; 5():456. PubMed ID: 25620979
[TBL] [Abstract][Full Text] [Related]
5. BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.
Choi H; Kim BG; Kim YH; Lee SJ; Lee YJ; Oh SP
Angiogenesis; 2023 Feb; 26(1):167-186. PubMed ID: 36348215
[TBL] [Abstract][Full Text] [Related]
6. Arterial endoglin does not protect against arteriovenous malformations.
Singh E; Redgrave RE; Phillips HM; Arthur HM
Angiogenesis; 2020 Nov; 23(4):559-566. PubMed ID: 32506200
[TBL] [Abstract][Full Text] [Related]
7. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
Mahmoud M; Borthwick GM; Hislop AA; Arthur HM
Lab Invest; 2009 Jan; 89(1):15-25. PubMed ID: 19015642
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
Karlsson T; Cherif H
Ups J Med Sci; 2018 Sep; 123(3):153-157. PubMed ID: 30251589
[TBL] [Abstract][Full Text] [Related]
9. Brain arteriovenous malformation in hereditary hemorrhagic telangiectasia: Recent advances in cellular and molecular mechanisms.
Drapé E; Anquetil T; Larrivée B; Dubrac A
Front Hum Neurosci; 2022; 16():1006115. PubMed ID: 36504622
[TBL] [Abstract][Full Text] [Related]
10. Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models--brief report.
Garrido-Martin EM; Nguyen HL; Cunningham TA; Choe SW; Jiang Z; Arthur HM; Lee YJ; Oh SP
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2232-6. PubMed ID: 25082229
[TBL] [Abstract][Full Text] [Related]
11. SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2.
Ola R; Künzel SH; Zhang F; Genet G; Chakraborty R; Pibouin-Fragner L; Martin K; Sessa W; Dubrac A; Eichmann A
Circulation; 2018 Nov; 138(21):2379-2394. PubMed ID: 29976569
[TBL] [Abstract][Full Text] [Related]
12. Enhanced responses to angiogenic cues underlie the pathogenesis of hereditary hemorrhagic telangiectasia 2.
Choi EJ; Kim YH; Choe SW; Tak YG; Garrido-Martin EM; Chang M; Lee YJ; Oh SP
PLoS One; 2013; 8(5):e63138. PubMed ID: 23675457
[TBL] [Abstract][Full Text] [Related]
13. Executive summary of the 14th HHT international scientific conference.
Ola R; Hessels J; Hammill A; Friday C; Clancy M; Al-Samkari H; Meadows S; Iyer V; Akhurst R
Angiogenesis; 2023 Aug; 26(Suppl 1):27-37. PubMed ID: 37695357
[TBL] [Abstract][Full Text] [Related]
14. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
[TBL] [Abstract][Full Text] [Related]
15. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.
Ardelean DS; Letarte M
Front Genet; 2015; 6():35. PubMed ID: 25717337
[TBL] [Abstract][Full Text] [Related]
17. SMAD4 Deficiency Leads to Development of Arteriovenous Malformations in Neonatal and Adult Mice.
Kim YH; Choe SW; Chae MY; Hong S; Oh SP
J Am Heart Assoc; 2018 Nov; 7(21):e009514. PubMed ID: 30571376
[TBL] [Abstract][Full Text] [Related]
18. Differential Expression of Circulating Plasma miRNA-370 and miRNA-10a from Patients with Hereditary Hemorrhagic Telangiectasia.
Ruiz-Llorente L; Albiñana V; Botella LM; Bernabeu C
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899377
[TBL] [Abstract][Full Text] [Related]
19. Potential Second-Hits in Hereditary Hemorrhagic Telangiectasia.
Bernabeu C; Bayrak-Toydemir P; McDonald J; Letarte M
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33167572
[TBL] [Abstract][Full Text] [Related]
20. A Microphysiological HHT-on-a-Chip Platform Recapitulates Patient Vascular Lesions.
Fang JS; Hatch CJ; Andrejecsk J; Trigt WV; Juat DJ; Chen YH; Matsumoto S; Lee AP; Hughes CCW
bioRxiv; 2024 Mar; ():. PubMed ID: 38559155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
